Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Fineline Cube Feb 26, 2026
Company Deals

GSK to Acquire 35Pharma for $950M – Adds Potential Best‑in‑Class PAH Asset HS235

Fineline Cube Feb 26, 2026
Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

3SBio’s SSGJ-611 NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis

Fineline Cube Feb 26, 2026
Company Drug

Kexing Biopharma’s GB19 Wins NMPA IND Approval – Novel BDCA2 Targeted Therapy for Lupus Enters Clinic

Fineline Cube Feb 26, 2026
Company Deals

Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures

Fineline Cube Nov 4, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the decision not to proceed with a...

Policy / Regulatory

China’s CDE Releases 88th Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Nov 4, 2024

The Center for Drug Evaluation (CDE) in China has announced its 88th batch of reference...

Company

AstraZeneca’s China President Leon Wang Confirmed to Assist in Investigation Amid Fraud Allegations

Fineline Cube Nov 3, 2024

On October 29, 2024, just hours after celebrating a business school anniversary on social media,...

Company Drug

Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial

Fineline Cube Nov 2, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for...

Company Drug

Shenzhen Chipscreen Biosciences’ Tivozanib Secures NMPA Approval for ES-SCLC Phase III Trial

Fineline Cube Nov 2, 2024

Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has announced that the National Medical Products Administration...

Company Drug

Humanwell Healthcare Receives NMPA Approval for Compound Sodium Lactate Ringer’s Injection

Fineline Cube Nov 2, 2024

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has received approval from the National Medical Products...

Policy / Regulatory

National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate

Fineline Cube Nov 1, 2024

The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than...

Company

MSD Reports 4% YOY Revenue Increase in Q3 2024, Led by Pharmaceutical Sector

Fineline Cube Nov 1, 2024

US pharmaceutical giant Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial...

Company

Regeneron Pharmaceuticals Reports 11% YOY Revenue Growth in Q3 2024

Fineline Cube Nov 1, 2024

US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of...

Company Deals

AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer

Fineline Cube Nov 1, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...

Company Drug

CARsgen Therapeutics’ Suspended CAR-T Therapies Get FDA Green Light to Resume

Fineline Cube Nov 1, 2024

The US Food and Drug Administration (FDA) has removed the suspension on clinical studies for...

Company Drug

AIM Vaccine Submits Market Filing for 13-Valent Pneumococcal Conjugate Vaccine in China

Fineline Cube Nov 1, 2024

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the submission of a market filing...

Company Drug

Eisai and Biogen Complete BLA Submission for Alzheimer’s Drug Leqembi to FDA

Fineline Cube Nov 1, 2024

Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the completion...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Shows Positive One-Year Results in TRAVEL II Study

Fineline Cube Nov 1, 2024

Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced the...

Company

Biogen Reports Q3 2024 Sales Dip, Raises Full-Year Guidance

Fineline Cube Nov 1, 2024

US biotechnology company Biogen Inc. (NASDAQ: BIIB) reported global sales of USD 2.466 billion for...

Company Drug

Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study

Fineline Cube Nov 1, 2024

China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the US...

Company Deals

HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales

Fineline Cube Nov 1, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...

Company Drug

Zhejiang Huahai Pharmaceutical Gets New Zealand Approval for Asthma Bispecific Antibody Trial

Fineline Cube Nov 1, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval in New...

Company Drug

Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study

Fineline Cube Nov 1, 2024

China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...

Company Drug

Innovent Biologics Reports Q3 2024 Sales Exceeding RMB 2.3 Billion, Up 40% YOY

Fineline Cube Nov 1, 2024

China-based Innovent Biologics Inc., (HKG: 1801) has announced product sales exceeding RMB 2.3 billion (USD...

Posts pagination

1 … 235 236 237 … 627

Recent updates

  • Novartis to Build $23B RLT Manufacturing Site in Texas – Expands Radioligand Therapy Production Capacity
  • Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation
  • 3SBio’s SSGJ-611 NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis
  • Kexing Biopharma’s GB19 Wins NMPA IND Approval – Novel BDCA2 Targeted Therapy for Lupus Enters Clinic
  • Lepu Biopharma’s GPC3 ADC MRG006A Wins NMPA Approval for HCC Combination Trials – First‑in‑Class Asset Advances
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Novartis to Build $23B RLT Manufacturing Site in Texas – Expands Radioligand Therapy Production Capacity

Company Deals

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Company Drug

3SBio’s SSGJ-611 NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis

Company Drug

Kexing Biopharma’s GB19 Wins NMPA IND Approval – Novel BDCA2 Targeted Therapy for Lupus Enters Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.